Literature DB >> 19811805

High prevalence of extended-spectrum beta-lactamase-producing enterobacteriaceae in bacteremia after transrectal ultrasound-guided prostate biopsy: a need for changing preventive protocol.

Juan P Horcajada1, Marcos Busto, Santiago Grau, Luisa Sorlí, Roser Terradas, Margarita Salvadó, Jośe A Lorente, Araceli González, Hernando Knobel.   

Abstract

OBJECTIVES: To determine whether the incidence of bacteremia after transrectal ultrasound-guided prostate biopsy (TRUSGPB) significantly diminishes with the setting up of a new preventive protocol. This protocol was set up after detecting an augmented incidence of bacteremia after TRUSGPB with a high prevalence of antibiotic-resistant microorganisms.
METHODS: Retrospective descriptive and prospective intervention study performed at a University Hospital. PARTICIPANTS: Patients undergoing TRUSGPB under the old preventive protocol (January 2006-February 2007), that is, amoxicillin-clavulanate 500 mg tid the day before, the day of the procedure, and 1 day after the procedure, and after setting up a new protocol (March 2007-April 2008), that is, 2 g cefoxitin 1 hour before the procedure and ciprofloxacin 750 mg p.o. bid the day before, the day of the procedure, and 3 days after the procedure; dipstick urinalysis was performed before the procedure, and patients with positive results were not biopsied.
RESULTS: Incidence of bacteremia with old and new protocols: 9 of 204 procedures (4.4%) vs 2 of 207 (0.9%), (P = .03). Four isolates (44.4%) under the old protocol produced extended-spectrum beta-lactamase (ESBL). With the new protocol, 2 (0.9%) cases of non-ESBL Escherichia coli bacteremia were observed. Sixty-five (23.8%) cases were not biopsied because of positive result of dipstick urinalysis, lack of antibiotic prophylaxis adherence, or altered coagulation parameters.
CONCLUSIONS: Antibiotic prophylaxis for TRUSGPB should take into account local resistance patterns. Cefoxitin could be used as prophylaxis in centers with high prevalence of ESBL enterobacteriaceae. Before TRUSGPB, excluding patients with positive results of dipstick urinalysis is an advisable practice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19811805     DOI: 10.1016/j.urology.2009.06.061

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  17 in total

1.  Infection: prostate biopsy-infection and prior fluoroquinolone exposure.

Authors:  Michael A Liss
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

Review 2.  Prevention and treatment of biopsy-related complications.

Authors:  Ramgopal Satyanarayana; Dipen Parekh
Journal:  Curr Urol Rep       Date:  2014-02       Impact factor: 3.092

3.  Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer.

Authors:  Andre C King; Andrew Livermore; Timo A J Laurila; Wei Huang; David F Jarrard
Journal:  Urol Oncol       Date:  2011-08-03       Impact factor: 3.498

4.  Bacterial sepsis following prostatic biopsy.

Authors:  Luca Carmignani; Stefano Picozzi; Matteo Spinelli; Salvatore Di Pierro; Gabriella Mombelli; Ercole Negri; Milvana Tejada; Paola Gaia; Elena Costa; Augusto Maggioni
Journal:  Int Urol Nephrol       Date:  2012-02-28       Impact factor: 2.370

Review 5.  The augmented prophylactic antibiotic could be more efficacious in patients undergoing transrectal prostate biopsy: a systematic review and meta-analysis.

Authors:  Lu Yang; Zhuang Tang; Liang Gao; Tao Li; Yongji Chen; Liangren Liu; Ping Han; Xiang Li; Qiang Dong; Qiang Wei
Journal:  Int Urol Nephrol       Date:  2016-05-09       Impact factor: 2.370

6.  Reducing Infectious Complications Following Transrectal Ultrasound-guided Prostate Biopsy: A Systematic Review.

Authors:  Jordon T Walker; Nirmish Singla; Claus G Roehrborn
Journal:  Rev Urol       Date:  2016

7.  Detection of fluoroquinolone-resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy.

Authors:  Michael A Liss; Amy N Peeples; Ellena M Peterson
Journal:  J Clin Microbiol       Date:  2010-12-22       Impact factor: 5.948

8.  Fluoroquinolone-resistant acute prostatitis requiring hospitalization after transrectal prostate biopsy: effect of previous fluoroquinolone use as prophylaxis or long-term treatment.

Authors:  Sinan Ekici; Melahat Cengiz; Güven Turan; Esra Ergün Alış
Journal:  Int Urol Nephrol       Date:  2011-05-06       Impact factor: 2.370

9.  Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy.

Authors:  Michael A Liss; Alexandra Chang; Rosanne Santos; Amy Nakama-Peeples; Ellena M Peterson; Kathryn Osann; John Billimek; Richard J Szabo; Atreya Dash
Journal:  J Urol       Date:  2011-02-22       Impact factor: 7.450

Review 10.  Optimization of prostate biopsy: review of technique and complications.

Authors:  Marc A Bjurlin; James S Wysock; Samir S Taneja
Journal:  Urol Clin North Am       Date:  2014-05       Impact factor: 2.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.